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Abstract: A retrospective data analysis was conducted to evaluate the usefulness of baseline
characteristics in predicting treatment response to antidepressant medication in 97 outpatients
with nonpsychotic major depression treated for up to sixteen weeks with nefazodone. Baseline
demographics (gender), illness features (symptom severity, length of illness, length of current
episode, number of episodes, age of onset, longitudinal subtype, endogenicity, melancholia,
family history of mood disorders), and social features (living status) were evaluated. Response
to treatment was defined as a ≥ 50% reduction in the 17-item Hamilton Rating Scale for
Depression (HRSD17) score. The results of a survival analysis indicated that patients with
shorter histories of illness (< 4 years), a negative family history of depression, and those who
were either married or were living with someone were more likely to have a positive outcome
during the acute phase treatment of depression. The main findings are consistent with extensive
previous literature indicating a better short-term outcome of depression where illness is shorter,
where there is no family history, and where there is better social support.
Keywords: antidepressant, treatment predictor, social support, major depression
Introduction
Studies attempting to identify moderators and mediators of treatment (Baron and
Kenny 1986; Kraemer et al 2002), such as baseline/pretreatment predictors of response
to antidepressants, have not yielded consistent findings (Bielski and Friedel 1976;
Greenhouse et al 1987; Katz et al 1987; Croughan et al 1988; Hooley and Teasdale
1989; Joyce and Paykel 1989; Kocsis et al 1989, 1990; Brugha et al 1990; Danish
University Antidepressant Group 1990; Vallejo et al 1991; Keller et al 1992; Goodwin
1993; Hoencamp et al 1994; Friedman et al 1995; Baldwin et al 1996; Cohn et al
1996; Aliapoulous and Zisook 1996; Nierenberg 2003). The identified clinical
predictors have typically fallen into the following categories: (1) demographic
characteristics (gender); (2) illness features (severity at baseline, length of illness,
age of onset, length of current episode, number of episodes, longitudinal subtype,
endogenicity, melancholia, family history of mood disorders); and (3) social factors
(living status, social support).
Numerous illness characteristics have been found to be associated with a positive
response to antidepressant medications, including severity of depressive symptoms,
depressive subtypes, age at onset of illness, and past history of depressive episodes
(AHCPR 1993). Several studies have shown that specific features of psychiatric history
and of the current episode of depression influence treatment outcomes. Reimherr et
al (1990) found that patients with only a single episode of depression responded
slightly better to SSRI treatment than those with recurrent episodes (sertraline: 62%
vs 52%; amitriptyline: 66% vs 62%). Additionally, patients with melancholic features
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responded slightly better than those without such features
(sertraline: 56% vs 50%; amitriptyline: 63% vs 59%). Based
on a sample of patients with recurrent depression,
Greenhouse et al (1987) also found age, symptom severity,
and number of previous episodes associated with time to
sustained treatment response. The most extensively studied
area of treatment predictors includes history of illness
characteristics, such as number of previous episodes, length
of illness, and the presence of either single episode or
recurrent longitudinal subtypes. However, findings are not
consistent across all studies. Hoencamp et al (1994)
demonstrated that the baseline Hamilton Rating Scale for
Depression (HRSD) score was of greater significance in
predicting recovery than other variables, such as premorbid
history, symptomatology, and endogenous features (Danish
University Antidepressant Group 1986). Greenhouse et al
(1987) found that patients with high HRSD scores tended
to take longer to stabilize than patients with lower scores.
However, Pande and Sayler (1993) were unable to replicate
this finding. Conversely, patients with less severe depressive
illness have been shown to be more likely to respond to
amitriptyline or imipramine than those with severe
depressive illness (Croughan et al 1988). Family history has
also been found to be a prognostic indicator of outcomes.
When comparing patients who experience full interepisodic
recovery with partial and non-interepisodic recovery
patients, Akiskal (1982) found that patients with a family
history (first degree biological relative) of affective disorders
were more likely to have an incomplete recovery when
treated with tricyclic antidepressants.
In addition to illness features that predict treatment
response, researchers have attempted to examine the effects
of social or situational factors on treatment outcome. Direct
measures of social support and functioning, ie, Social
Adjustment Scale, Social and Occupational Functioning
Assessment Scale (Weissman and Bothwell 1976; APA
1994), and indirect measures such as living status have been
found to be positively related to response. Vallejo and
colleagues (1991) directly tested the effects of social support
on response after 6 weeks of medication treatment. They
found that patients treated with imipramine, with higher
levels of social support showed a greater percent decrease
in HRSD scores than patients with lower levels of social
support. Tomaszewska and colleagues (1996) obtained
similar results in a population of patients with non-
melancholic depression, and found higher levels of social
support in those patients who responded favorably
to treatment.
The vast majority of research evaluating the relationship
between social support and major depressive disorder
(MDD) has largely focused on the role played by social
support in improving clinical outcomes in general. Research
has not focused as much on patients being treated
specifically with antidepressant medications or psycho-
therapy. The relationship between social support and
psychological wellbeing has long been documented (Myers
et al 1975; Dean and Lin 1977; Andrews et al 1978; Cohen
and Wills 1985). Studies have suggested that social support
plays a significant role in mediating the development of
depressive symptoms by buffering the effects of negative
life events (Aneshensel and Stone 1982; Brown 1988;
George et al 1989; Zlotnick et al 1996). Brugha et al (1997)
found that patients with a longer course of illness, as
manifested by multiple recurrent episodes, reported
significantly lower levels of social support than patients with
a shorter course of illness. Ezquiaga et al (1998) found that
the psychological support provided by a spouse was
significant, with high levels of support being associated with
positive treatment outcomes. In a sample of 552 women
aged 18–65, Costello (1982) found that lack of intimacy
with a spouse or cohabitant and lack of a confidant were
associated with clinically significant levels of depression.
Hooley and Teasdale (1989) found, in a 9-month post-
hospitalization follow-up of patients with unipolar
depression, that patients with higher levels of marital discord
had significantly higher relapse rates. Coyne and colleagues
(2002) found higher levels of marital distress in depressed
females than in community controls. Interestingly, there
appear to be gender differences in the reporting of marital
distress, with depressed females reporting higher levels of
marital distress than their partners (Ensel 1982; Crowther
1985). In their 1992 study, Goering et al found that in a
population of women with MDD, few demographic or
clinical factors were related to the course of symptoms over
the 6-month study period. Recovery was predicted based
on the patients’ ratings of their current marital relationship
and by the spousal rating of their premorbid relationship.
The purpose of this study was to identify baseline
demographic, illness, and social features that predict
response to an antidepressant medication, nefazodone, in
patients with MDD. The demographic, illness, and social
feature predictors evaluated were: gender, age of onset,
severity at baseline, length of illness, length of current
episode, number of episodes, longitudinal subtype,
endogenicity, melancholia, family history of mood disorders,
and living status.Neuropsychiatric Disease and Treatment 2005:1(1) 53
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Methods
Subjects
Participants in this study were 97 outpatients with MDD:
59 females and 38 males, age 38.5 ± 10.0 (mean + SD). They
were treated for up to sixteen weeks with nefazodone in the
Department of Psychiatry, The University of Texas
Southwestern Medical Center, Dallas, USA. This sample
has been reported as part of a larger multicenter trial (Trivedi
et al 2001). Prior to interview, all patients provided written
informed consent. All participants met the Structured
Clinical Interview for DSM-III-R (SCID) (Spitzer et al 1992)
criteria for MDD and were 18 years of age or older. The
duration of the current major depressive episode was ≥ 6
months. Patients with bipolar disorder, seasonal affective
disorder, substance abuse or dependence disorders, as well
as those with delusions or hallucinations during the current
episode, were excluded. Patients judged to be at serious risk
of suicide and those with a concurrent diagnosis of organic
mental syndrome, schizophrenia, or any other psychotic
disorder, were not included in the sample. All patients had
a 17-item Hamilton Rating Scale for Depression (HRSD17)
(Hamilton 1960, 1967) score ≥ 20 at the baseline evaluation.
See Table 1.
Procedures
Patients were evaluated at baseline using a SCID to obtain
demographic (age and gender), social (living status), and
illness features (length of episode, depressive subtype,
age at onset, recurrence, length of illness, number of
episodes, family history of depression). Melancholia was
characterized based on the SCID (Spitzer et al 1992), and
endogenicity was defined using the Research Diagnostic
Criteria (Spitzer et al 1977). Symptom severity was assessed
at baseline using the HRSD17 and the thirty-item Inventory
of Depressive Symptomatology – Clinician Rated (IDS-C30)
(Rush et al 1986, 1996) and again with the HRSD17 at weeks
1, 2, 3, 4, 6, 8, 10, 12, and 16. Nefazodone was administered
twice daily for 12 weeks. Dosages were titrated up to
400 mg/day by the end of the second week. Patients not
responding to the initial titration schedule were titrated to
500 or 600 mg/day after week 3. Patients were restricted
from concomitant use of other drugs except lorazepam,
temazepam, or oxazepam.
Statistical analysis
Cox’s proportional hazard models (Cox 1972) were used to
test for differences in treatment response for a series of
demographic, social support, and illness features. The
demographic characteristic and social support predictors
evaluated were gender and living status, respectively. Illness
features included length and severity of current episode,
length of illness, number of episodes, age at onset,
longitudinal subtype, endogenicity (Spitzer et al 1977),
melancholia (Spitzer et al 1992), and family history of
mood disorders. For these analyses response to treatment
was defined as a > 50% reduction in the baseline HRSD
total score.
Table 1 Predictors of response to antidepressants: baseline
Predictors of response n Mean SD %
Age 97 38.5 10.0
Females/Males 97 60.8/39.2
Marital status 97
Single 19.6
Engaged 1.0
Married 37.1
Cohabiting 8.2
Divorced 32.0
Widowed 2.1
HRSD at baseline 97 23.9 2.1
Age at onset 96 25.1 11.0
Length of illnessa 96 13.2 9.7
Length of current episode 97 67.0 75.8
Number of episodes 95 2.3 1.9
Single/Recurrent 95 40.0/60.0
Endogenous/Nonendogenous 81 42.0/58.0
Melancholic/Nonmelancholic 97 43.3/56.7
Family history of affective
disorder(Positive/Negative) 94 36.2/63.8
a Months.
Abbreviation: HRSD, Hamilton Rating Scale for Depression.
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Figure 1 Estimated likelihood of response based on Cox’s regression analyses
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length of the current episode (0–48 months vs > 49 months
(this median split provided sample size for the two groups
to make a reasonable comparison)); endogenous vs
nonendogenous; and melancholic vs nonmelancholic.
Length of the current episode revealed that patients whose
current episode was less than 4 years were more likely to
respond (70%) than those with longer current episodes
(62%). This effect was marginally significant (χ2 = 3.2,
df = 1, p < 0.08). Dropout rates were about the same for these
two groups (28% and 26%, respectively). Since chronic
depression has been defined as episodes lasting 2 years or
more, a secondary analysis was conducted using a 24-month
threshold to distinguish short vs longer current episodes.
No statistically significant differences were found. Baseline
severity, endogenicity, and the presence of melancholia were
not significantly related to treatment response.
Four measures were used to define strata based on history
of illness (single vs recurrent; age at onset: 1–19 vs 20 or
older; length of illness: 0–9 years vs > 10 years; and number
of episodes: 1 vs 2 vs 3 or more). Length of illness was
significantly related (χ
2 = 5.2, df = 1, p < 0.03) to outcome.
Patients with shorter illnesses were more likely to respond
than those with longer illnesses (see Figure 2). Single
versus recurrent depression, age of onset, and number
of episodes were not significantly related to treatment
response.
Strata were created based on a positive versus negative
family history of major mood disorders in first-degree
relatives. There was a significant difference based on family
history (χ
2 = 4.6, df = 1, p < 0.04). Patients with a negative
family history were more likely to respond (77%) than those
with a positive family history (62%) (see Figure 2). Dropout
rates before completing 16 weeks of treatment were similar
(21% and 30%, respectively).
Analyses of combined predictors
To explore the relationships between individual baseline
features that predicted response, survival analysis was
conducted and included all three individual predictors:
marital status, length of illness, and family history. Once
living status entered the model, no other predictors
significantly improved the model. Thus, there was
substantial overlap between these individual predictors, as
might be expected in this relatively small sample. The
parallel analyses conducted using an HRSD score ≥ 10
criteria produced the same results for living status (χ2 = 7.7,
df = 1, p < 0.006) and length of illness (χ
2 = 4.3, df = 1,
Results
Demographic and social features
The analysis of living status indicated better response to
treatment for the married patients (married or cohabiting)
than those patients living alone (single, engaged, divorced,
widowed): 84% and 51%, respectively (χ
2 = 6.9, df = 1,
p < 0.009). While the response rates were similar in the first
few weeks of treatment, after week 4, married patients show
clearly higher rates of response than the unmarried patients
(see Figure 1). This result is qualified by differences in the
dropout rates (single, 34%; married, 14%). There was no
statistically significant effect for gender. See Table 2.
Illness features
Four predictors were used to create a test for differences in
response based on characteristics of the current depressive
episode: severity (HRSD score 20–23 vs HRSD score ≥ 24);
Table 2 Predictors of response to antidepressants and
baseline HRSD
Baseline HRSD
Predictors of response n Mean SD
Gender
Female 59 23.9 2.2
Male 38 23.8 2.1
Marital statusa
Unmarried 53 23.9 1.9
Married 44 23.8 2.4
Age at onset
0–19 40 23.8 2.1
20+ 56 23.9 2.2
Length of illnessa
0–9 42 24.1 2.4
10+ 54 23.7 1.9
Length of current episode
0–48 50 24.0 2.2
49+ 47 23.7 2.1
Number of episodes
1 40 23.9 2.1
2 26 23.9 2.6
3+ 30 23.8 1.9
Single 38 23.9 2.1
Recurrent 57 23.8 2.2
Endogenous 34 23.3 1.4
Nonendogenous 47 24.4 2.7
Melancholic 42 24.5 2.5
Nonmelancholic 55 23.4 1.7
Family history of affective disorder
Positive 34 23.8 2.4
Negative 60 23.9 2.0
a p < 0.05 comparing 2 subgroups (survival analysis).
Abbreviation: HRSD, Hamilton Rating Scale for Depression.Neuropsychiatric Disease and Treatment 2005:1(1) 55
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p < 0.04). A significant difference, as opposed to a marginal
difference, was found for length of episode (χ
2 = 4.3, df = 1,
p < 0.04). Only one major difference was found for the single
vs recurrent depression groups. A significant difference was
found using this response criterion (χ
2 = 4.6, df = 1, p < 0.04).
Patients with a recurrent history responded better than those
in their first episode.
Discussion
The results of this study suggest that three easily discernable
patient characteristics can help predict a patient’s response
to antidepressant medication, in this case, nefazodone. The
characteristics found to be most useful were, living status,
total length of illness, and family history of depression. The
findings associated with illness features are consistent with
previous studies reporting longer current episodes associated
with a lower likelihood of response to antidepressants
(Bielski and Friedel 1976; Rush et al 1983; Keller et al 1984,
1992).
Although more elaborate methods of outcome prediction
such as receptor analysis or neuroimaging (Espisito and
Goodnick 2003) may be useful, they have not yet led to
consistent findings and are very likely not to be practical in
routine clinical practice. The results of this study suggest,
simple, easy to obtain data, such as marital status, show
great promise in the prediction of response to antidepressant
treatment. Interestingly, in our sample, being married or
living together appeared to have a profound positive effect
on the overall response rates, with married or cohabiting
patients meeting criteria for treatment response with greater
frequency than their single cohorts. Living status also had
an impact on the patients’ willingness to stay in treatment.
The married/cohabiting group remained in treatment longer
even in the absence of response, a finding consistent with
Hagerty and Williams (1999) who found patients living
alone were more likely to drop out of treatment. Numerous
drug utilization studies have shown that over 45%–50% of
patients who start an antidepressant are not in treatment by
3 months, suggesting a strong need to be able to
preemptively identify predictors of not only response but
also dropouts. While not all studies have found social
support to be a significant predicator of treatment outcome
(Hirshfeld et al 1986; George et al 1989), the majority of
the studies have suggested social support and even more
specifically marital status as positive predictors of response.
The quality of the marital relationship also provides a
significant aid in predicting treatment response. Moreover,
recent data from a number of studies (Hunkeler et al 2000;
Unutzer et al 2002; Trivedi et al 2004) suggest there is a
clear benefit for a disease management approach in the
treatment of depression. These studies have emphasized
more frequent patient contact as well as more robust
psychosocial and educational support for patients to enhance
adherence, improve the patient’s ability to self-monitor their
symptoms, and increase patients’ understanding of the
chronic medical illness nature of their depressive disorders.
These data thus provide another dimension of evidence that
optimal outcome can be enhanced if pharmacotherapy is
augmented with social support.
The current study is limited by several factors including
a moderate sample size, the use of only one antidepressant
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Figure 2 Estimated likelihood of response based on Cox’s regression analyses
for length of illness and family history of depression.Neuropsychiatric Disease and Treatment 2005:1(1) 56
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medication, and the lack of a placebo control group. It is
also possible that factors indicating a chronic and or severe
disorder like length of illness may predict poorer outcome
irrespective of the treatment(s) used. Moreover, it is also
likely that social support, life stressors, and family history
of psychiatric comorbidity are indicators of positive outcome
for MDD across various treatment modalities and may also
increase the chances of spontaneous response. Therefore,
in the absence of a placebo or an active control, the
demographic and clinical features identified may be thought
of as good prognostic predictors of outcome independent
of treatment modality. Despite these limitations, the current
study does provide additional support for the hypothesis
that easy to identify patient factors may be able to
significantly improve the quality of patient care by
increasing physician efficiency when prescribing anti-
depressant medications. These clinical predictors, although
not prescriptive, can assist in treatment planning and aid
with patient education regarding potential outcomes. Of the
three clinical predictors identified (living status, total length
of illness, and family history of depression), living status
appears to be the most promising mediator of treatment
outcome. Future study of clinical predictors of treatment
response for emerging antidepressant medications should
include social features, such as living status and an
assessment of the quality of relationships, in addition to the
commonly used demographic and illness features in
predictor analyses.
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